HER2+ Breast Cancer: Applying Recent Data Updates at ASCO 2024 into Clinical Practice - Episode 8

Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges

, , , ,

Ian Krop, MD, PhD, provides an overview of HER2-low and HER2 ultra-low breast cancer and discusses challenges encountered during diagnosis.

EP. 1: Challenges in Diagnosing HER2+ Breast Cancer
EP. 2: Neoadjuvant Treatment Options in HER2+ Early Breast Cancer
EP. 3: Preoperative Monitoring and Surgical Options for HER2+ Patients
EP. 4: Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer
EP. 5: Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC
EP. 6: Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer
EP. 7: Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets
Now Viewing
EP. 8: Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges
EP. 9: Overview of DESTINY-Breast06
EP. 10: Clinical Perspectives on Managing ILD Related to T-DXd
EP. 11: Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC
EP. 12: Unmet Needs and Future Direction in HER2+ Breast Cancer

Video content above is prompted by the following question:

  • Please define HER2 low and HER2 ultra-low. What are some challenges when diagnosing these?

Related Content:

HER2+ Breast Cancer: Applying Recent Data Updates at ASCO 2024 into Clinical PracticeBaylor Scott & White Charles A. Sammons Cancer Center UCLA Health Jonsson Comprehensive Cancer CenterYale Cancer CenterVCU Massey Cancer CenterBreast CancerOncLive Peer Exchange®
Dr O’Regan on Sequencing Considerations in Advanced HR+ Breast Cancer
STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers
Ongoing and Planned Research Build on Prior Advancements in ER+/HER2– Breast Cancer